Literature DB >> 20456746

Association of growth factors with arterial recanalization and clinical outcome in patients with ischemic stroke treated with tPA.

T Sobrino1, M Millán, M Castellanos, M Blanco, D Brea, L Dorado, R Rodríguez-González, M Rodríguez-Yáñez, J Serena, R Leira, A Dávalos, J Castillo.   

Abstract

SUMMARY
BACKGROUND: Growth factors (GF) such as vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and granulocyte-colony stimulating factor (G-CSF) have been associated with greater efficacy of tissue plasminogen activator (tPA) in experimental studies.
OBJECTIVES: To study the association of these GF with arterial recanalization and clinical outcome in patients with acute ischemic stroke treated with tPA.
METHODS: We prospectively studied 79 patients with ischemic stroke attributable to MCA occlusion treated with i.v. tPA within the first 3 h from onset of symptoms. Continuous transcranial color-coded sonography (TCCS) was performed during the first 2 h after tPA bolus to assess early MCA recanalization. Hemorrhagic transformation (HT) was classified according to ECASS II definitions. Good functional outcome was defined as a Rankin scale score of 0-2 at 90 days. GF levels were determined by ELISA.
RESULTS: Mean serum levels of VEGF, G-CSF and Ang-1 at baseline were significantly higher in patients with early MCA recanalization (n = 30) (all P < 0.0001). In the multivariate analysis, serum levels of VEGF (OR, 1.03), G-CSF (OR, 1.02) and Ang-1 (OR, 1.07) were independently associated with early MCA recanalization (all P < 0.0001). On the other hand, patients with parenchymal hematoma (PH) (n = 20) showed higher levels of Ang-1 (P < 0.0001). Ang-1 (OR, 1.12; P < 0.0001) was independently associated with PH, whereas patients with good outcome (n = 38) had higher levels of G-CSF (P < 0.0001). G-CSF was independently associated with good outcome (OR, 1.12; P = 0.036).
CONCLUSIONS: These findings suggest that GF may enhance arterial recanalization in patients with ischemic stroke treated with t-PA, although they might increase the HT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456746     DOI: 10.1111/j.1538-7836.2010.03897.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.

Authors:  Ike dela Peña; Cesar V Borlongan
Journal:  Transl Stroke Res       Date:  2015-12       Impact factor: 6.829

Review 2.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

3.  Cerebrospinal fluid vascular endothelial growth factor.

Authors:  Peter T Nelson; Gregory A Jicha
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

Review 4.  Adjunctive Therapy Approaches for Ischemic Stroke: Innovations to Expand Time Window of Treatment.

Authors:  Talia Knecht; Jacob Story; Jeffrey Liu; Willie Davis; Cesar V Borlongan; Ike C Dela Peña
Journal:  Int J Mol Sci       Date:  2017-12-19       Impact factor: 5.923

Review 5.  Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need.

Authors:  Ike Dela Peña; Cesar Borlongan; Guofang Shen; Willie Davis
Journal:  J Stroke       Date:  2017-01-31       Impact factor: 6.967

6.  Hemorrhagic Transformation in Acute Ischemic Stroke: A Quantitative Systematic Review.

Authors:  Asaf Honig; Jennifer Percy; Amir A Sepehry; Alejandra G Gomez; Thalia S Field; Oscar R Benavente
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

Review 7.  Unraveling the potential of endothelial progenitor cells as a treatment following ischemic stroke.

Authors:  Antía Custodia; Alberto Ouro; João Sargento-Freitas; Marta Aramburu-Núñez; Juan Manuel Pías-Peleteiro; Pablo Hervella; Anna Rosell; Lino Ferreira; José Castillo; Daniel Romaus-Sanjurjo; Tomás Sobrino
Journal:  Front Neurol       Date:  2022-09-08       Impact factor: 4.086

Review 8.  Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator.

Authors:  Talia Knecht; Cesar Borlongan; Ike Dela Peña
Journal:  Brain Circ       Date:  2018-10-09

Review 9.  Blood Biomarkers of Parenchymal Damage in Ischemic Stroke Patients Treated With Revascularization Therapies.

Authors:  Benedetta Piccardi; Silvia Biagini; Veronica Iovene; Vanessa Palumbo
Journal:  Biomark Insights       Date:  2019-12-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.